BSRT Graduate School
Thomas Blankenstein
 |
| Organisation: | Charité - Universitätsmedizin Berlin |
| Institute: | Institute of Immunology |
| Address: | Hindenburgdamm 30 12200 Berlin |
| Campus: | |
| Website: | www.mdc-berlin.de/en/research/research_teams/molecular_immunology_and_gene_therapy/ |
| Positions: | Since 2000 Director of the Institute of Immunology, Charité - Universitätsmedizin Berlin Since 1993 Research group leader at the Max Delbrück Center for Molecular Medicine (MDC), Berlin |
| Research Interests: | Most of the current experimental cancer models do not reflect the pathophysiology of real-life cancer. Cancer usually occurs sporadically and is clonal in origin. Between tumor initiation and progression clinically unapparent pre-malignant cells may persist for years or decades in humans. More recently, mouse models of sporadic cancer have been developed. The mouse germ-line can be engineered with high precision so that defined genes can be switched on and off in the adult organism, ideally in a locally and timely controlled fashion. However, analysis of the immune response against sporadic tumors requires the knowledge of a tumor antigen. |
| Publications: | selected list Czéh M, Loddenkemper C, Shalapour S, Schön C, Robine S, Goldscheid E, Stein H, Schüler T, Willimsky G, Blankenstein T. The immune response to sporadic colorectal cancer in a novel mouse model. Oncogene. 2010 Dec 16;29(50):6591-602 Shalapour S, Deiser K, Sercan O, Tuckermann J, Minnich K, Willimsky G, Blankenstein T, Hämmerling GJ, Arnold B, Schüler T. Commensal microflora and interferon-gamma promote steady-state interleukin-7 production in vivo. Eur J Immunol. 2010 Sep;40(9):2391-400 Kammertoens T, Blankenstein T. Making and circumventing tolerance to cancer. Eur J Immunol. 2009 Sep;39(9):2345-53 Search for publications of Prof. Blankenstein in PubMed |
